Effects on α‐ and β‐cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study

Aims To investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of α‐ and β‐cell function in people with type 2 diabetes mellitus ( T2DM ) insufficiently controlled on metformin monotherapy. Research design and methods A total of 44 people with T2DM received 25 mg empagliflozin for a duration of 1 month in an open‐label fashion (treatment period 1 [ TP1 ]). Thereafter, they were...